Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck extends FoxHollow pact
October 2, 2006
| A version of this story appeared in
Volume 84, Issue 40
Merck and FoxHollow Technologies will expand the scope of their collaboration on atherosclerotic plaque analysis. Merck will pay the medical device company $40 million over four years in exchange for an exclusive collaboration in specified disease areas. Merck will provide $60 million in research funding over the next three years and will pay an additional $10 million annually to extend the agreement after the initial four years. Merck will also buy $95 million in FoxHollow stock. Under a partnership announced last year, Merck has been using plaque analysis to identify biomarkers and novel targets to treat atherosclerosis.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X